Nitroquick (Glyceryl Trinitrate)

Glyceryl trinitrate releases nitric oxide in vascular smooth muscle, which activates guanylate cyclase and raises cyclic GMP levels. The increase in cyclic GMP causes relaxation of veins and arteries, lowering cardiac preload and afterload, and ultimately reducing the heart’s oxygen demand during ischemic episodes.

The dose of Nitroquick is individualized by the prescribing clinician based on the patient’s condition, severity of angina, and response to therapy. The prescriber determines the appropriate strength, frequency, and duration of treatment, and patients should follow the specific instructions provided on the prescription label.

Safety data for Nitroquick during pregnancy and lactation are limited, and the pregnancy category is listed as unknown. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Nitroquick, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details and any necessary import documentation.

Nitroquick (glyceryl trinitrate) provides rapid, short‑acting relief of angina, whereas other nitrates such as isosorbide dinitrate have longer durations of action. Compared with non‑nitrate agents like beta‑blockers or calcium‑channel blockers, Nitroquick works primarily by vasodilation and reducing myocardial oxygen demand, offering a quick onset but requiring careful monitoring for tolerance.

Nitroquick should be stored below 25 °C in its original packaging, protected from moisture and direct light. Keep the product in a dry place and avoid exposing it to high humidity or temperature extremes, which could affect its stability and efficacy.

Nitroquick is placed under the tongue (sublingual) and allowed to dissolve completely. The patient should not swallow the tablet whole, as absorption is optimized through the oral mucosa. After dissolution, the patient should remain seated or lying down to reduce the risk of dizziness or fainting.

The most serious adverse events include severe hypotension, syncope (fainting), and methemoglobinemia, a rare condition that impairs oxygen delivery. Patients should be educated to recognize signs of very low blood pressure, such as light‑headedness, and to seek immediate medical attention if these occur.

Nitroquick should be avoided in individuals with known hypersensitivity to nitrates, severe hypotension, or those currently taking phosphodiesterase‑5 inhibitors (e.g., sildenafil). Caution is also advised for patients with recent head trauma, increased intracranial pressure, or severe anemia, as these conditions may exacerbate adverse effects.